Therapeutic Strategies in Alzheimer’s Disease: Ml Muscarinic Agonists
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The cholinergic hypofunction in Alzheimer's disease (AD) appears to be linked with two other major hallmarks of this disease, beta-amyloid and hyperphosphorylated tau protein. Formation of beta-amyloids might impair the coupling of M1 muscarinic acetylcholine receptors (mAChR) with G-proteins. This can lead to decreased signal transduction, a decrease of trophic and non-amyloidogenic amyloid precursor protein (APPs) and generation of more beta-amyloids, aggravating further the cholinergic deficiency. This review is an attempt to explore the M1 mAChR regulation of beta-amyloid metabolism, tau hyperphosphorylation and cognitive functions. The therapeutic potential of M1-selective muscarinic agonists including AF102B, AF150(S), AF267B (the AF series) is evaluated and compared, when possible, with several FDA-approved acetylcholinesterase inhibitors. These M1 agonists can elevate APPs, decrease tau protein phosphorylation/hyperphosphorylation in vitro and in vivo and restore cognitive impairments in several animal models for AD. Except for the M1 agonists, no other compounds were reported yet with combined effects; e.g., amelioration of cognition dysfunction and beneficial modulation of APPs/beta-amyloid together with tau hyperphosphorylation/phosphorylation. This property of M1 agonists to alter different aspects associated with AD pathogenesis could represent the most remarkable clinical value of such drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester
Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A. G., Greenberg, B. D., Siman, R., & Scott, R. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-05-01743.1998 · Cited by 213
Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited
Ladner, C. J., & Lee, J. M. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199808000-00001 · Cited by 142
Haring, R., Fisher, A., Marciano, D., Pittel, Z., Kloog, Y., Zuckerman, A., Eshhar, N., & Heldman, E. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052094.x · Cited by 122
Self-citationCholinergic deafferentation of the rabbit cortex: a new animal model of Aβ deposition
Beach, T. G., Potter, P. E., Kuo, Y.-M., Emmerling, M. R., Durham, R. A., Webster, S. D., Walker, D. G., Sue, L. I., Scott, S., Layne, K. J., et al. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00916-2 · Cited by 71
Eckols, K., Bymaster, F. P., Mitch, C. H., Shannon, H. E., Ward, J. S., & DeLapp, N. W. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02064-p · Cited by 53
Cited by
Auld, D. S., Kornecook, T. J., Bastianetto, S., & Quirion, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00079-5 · Cited by 666
Revisiting the cholinergic hypothesis in the development of Alzheimer's disease
Craig, L. A., Hong, N. S., & McDonald, R. J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.03.001 · Cited by 486
Therapeutic approaches to Alzheimer's disease
Klafki, H.-W., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 362
Martinez, A., Castro, A., Dorronsoro, I., & Alonso, M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10011 · Cited by 333
Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants
Ayaz, M., Sadiq, A., Junaid, M., Ullah, F., Subhan, F., & Ahmed, J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00168 · Cited by 281
Anti-Alzheimer’s Studies on β-Sitosterol Isolated from Polygonum hydropiper L.
Ayaz, M., Junaid, M., Ullah, F., Subhan, F., Sadiq, A., Ali, G., Ovais, M., Shahid, M., Ahmad, A., Wadood, A., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00697 · Cited by 220
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Kay, G. G., & Ebinger, U. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01849.x · Cited by 141
Villard, V., Espallergues, J., Keller, E., Vamvakides, A., & Maurice, T. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379286 · Cited by 139
Farías, G. G., Godoy, J. A., Hernández, F., Avila, J., Fisher, A., & Inestrosa, N. C. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.016 · Cited by 59
Self-citation
Metadata
- Authors
- Fisher, A.
- Venue
- Japanese Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2000
- Volume
- 84
- Issue
- 2
- Pages
- 101-112
- ISSN
- 0021-5198 (ISSN-L)
- OpenAlex
- W2047984053
- Cited by
- 80
- References
- 7
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.